Who
Georgia Erbez
Officer
Company insider
Files Form 4 as: Chief Financial Officer, Codexis; Director, Coherus Oncology; Director, Sierra Oncology; Chief Financial Officer, Harpoon Therapeutics; Director, Artelo Biosciences; CFO and Chief Business Officer, Zosano Pharma; Exec VP & CFO, Asterias Biotherapeutics; Chief Financial Officer, Raptor Pharmaceutical.
In numbers
- Trades disclosed
- 41
- Buys
- 8
- Sells
- 4
- Bought
- $559K
- Sold
- $134K
- Companies
- 8
- Companies where not an officer
- 3
- First trade
- 10 Sep 2012
- Last trade
- 12 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 14 Oct 2026 | CDXS CodexisChemicals | SEC FORM 4 Sold | $8,6196,335 at $1.36 | filing |
| 23 Feb 2026filed 25 Feb 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —316,100 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —316,100 at $0.00 | filing |
| 6 Feb 2026filed 9 Feb 2026 | CDXS CodexisChemicals | SEC FORM 4 Sold | $5,0013,826 at $1.31 | filing |
| 6 Feb 2026filed 9 Feb 2026 | CDXS CodexisChemicals | SEC FORM 4 Sold | $5,0123,826 at $1.31 | filing |
| 13 Oct 2025filed 15 Oct 2025 | CDXS CodexisChemicals | SEC FORM 4 Sold | $16K6,239 at $2.51 | filing |
| 12 Jun 2025filed 13 Jun 2025 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,000 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —161,250 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | —26,875 at $0.00 | filing |
| 10 Oct 2024filed 10 Oct 2024 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 10 Oct 2024filed 10 Oct 2024 | CDXS CodexisChemicals | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 4 Jun 2024filed 5 Jun 2024 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —114,000 at $0.00 | filing |
| 20 Feb 2024filed 22 Feb 2024 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,000 at $0.00 | filing |
| 1 Jul 2022filed 1 Jul 2022 | Sierra Oncologyoption or derivative | SEC FORM 4 Code D | —18,000 at $0.00 | filing |
| 28 Jan 2022filed 1 Feb 2022 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 11 Nov 2021filed 15 Nov 2021 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 22 Sep 2021filed 22 Sep 2021 | Harpoon Therapeutics | SEC FORM 4 Bought | $83K10,300 at $8.10 | filing |
| 2 Jun 2021filed 4 Jun 2021 | Sierra Oncologyoption or derivative | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 17 Feb 2021filed 18 Feb 2021 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 17 Feb 2021filed 18 Feb 2021 | Harpoon Therapeutics | SEC FORM 4 Code M | $53K25,000 at $2.12 | filing |
News
Codexis (NASDAQ:CDXS) and Revvity (NYSE:RVTY) Head-To-Head ComparisonCDXS · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Georgia Erbez; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.